HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASA Not Having Wrinkle-Reduction Claim For IMEDEEN Skin Supplement

This article was originally published in The Rose Sheet

Executive Summary

Studies submitted by Pfizer are inadequate to support the claim that IMEDEEN skin-care supplements “work from within to help reduce the appearance of fine lines and wrinkles,” the U.K. independent regulator says.

You may also be interested in...



Nutricosmetics Firms’ Science, Innovation May Win Over “Trusting” Youth

Exclusive online-only content>>>In a Datamonitor global survey of consumers between the ages of 18 and 34, 41% of respondents found nutricosmetic claims to be “somewhat or completely trustworthy,” signaling opportunity in a category that has been limited in part by consumer skepticism. Datamonitor researcher Aleksandrina Yotova profiles winning innovations and strategies in the niche nutricosmetics segment.

Nutricosmetics In U.S. On The Rise; Savvy Marketing Could Spur Uptake

At the SupplySide West conference and trade show in Las Vegas Nov. 7-8, industry experts shared their insights on the nutricosmetics market and offered advice for firms looking to attract consumers to the space.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel